Tenderwize
Back to tender search

Non-exclusive rebate agreement - Interferon beta-1a

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jun 30, 2027 · 308 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Interferon beta-1a (ATC-Code nach WHO: L03AB07)

30/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

30 / 100

Complexity

20 / 100

Risk factors

The buyer may terminate the open-house process if exclusive rebate agreements are concluded, ending all non-exclusive a...

No minimum purchase quantities; actual demand depends on prescribing doctors, patient numbers, and pharmacy behavior.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Conclusion of non-exclusive rebate agreements for Interferon beta-1a (intramuscular injection)
  • Open-house model: no exclusivity, no negotiation, no minimum volume
Show full summary

Non-exclusive drug rebate agreement under §130a(8) SGB V for Interferon beta-1a (L03AB07) via an open-house model. Any qualified pharmaceutical entrepreneur can participate without competition. No guaranteed volume, no exclusivity, and potential early termination if exclusive agreements are concluded. Contract ends 30.06.2027. First submission deadline 02.06.2025.

Risks

The buyer may terminate the open-house process if exclusive rebate agreements are concluded, ending all non-exclusive a...

No minimum purchase quantities; actual demand depends on prescribing doctors, patient numbers, and pharmacy behavior.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as per §4(18) AMG
  • Must have seat in EU/EEA (per §9(2) AMG)

Eligibility

  • Submit declaration of no exclusion grounds (§§123,124 GWB)

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria; open-house model - any qualified participant can join.

Buyer

Location

Erfurt, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive rebate agreement - Interferon beta-1a

Conclusion of non-exclusive rebate agreements for medicinal products containing Interferon beta-1a (ATC L03AB07) for intramuscular injection. Open-house model: no exclusivity, no negotiations, no guaranteed purchase volumes.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Jun 2025 - Jun 2027

Category

Pharmaceutical products

Award Criteria

No award criteria; open-house model - any qualified participant can join.

Deadline

Deadline Jun 30, 2027

Procurement Details

Publication date
17 Apr 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
254836-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3